BARDA Contract Funds Life-Saving TXA Injection Development
The Biomedical Advanced Research and Development Authority (BARDA) awarded Rafa Laboratories a landmark development contract valued at up to $186 million. This significant BARDA contract mandates the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA), a critical life-saving therapy used to control severe, uncontrolled bleeding. The partnership between the U.S. Department…










